Brief: IN8bio Announces First Patient Cohort Dosed In Phase 1 Clinical Trial Of INB-100
11/08/2021 13:42
Aug 11 (Reuters) - IN8bio Inc INAB.O :
* IN8BIO, INC. - ANNOUNCED COMPLETION OF DOSING OF FIRST
PATIENT
COHORT IN A PHASE 1 CLINICAL TRIAL OF INB-100
* IN8BIO, INC. - 3 PATIENTS COMPRISING FIRST COHORT DID NOT
EXPERIENCE ANY SEVERE ADVERSE INFUSION REACTIONS OR DOSE
LIMITING TOXICITIES TO DATE
Source text for Eikon: ID:nGNX3Qqt1f
Further company coverage: INAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IN8bio
See all newsIN8bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall